A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric

Project: Research project

Description

A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric
StatusActive
Effective start/end date12/1/183/31/25

Funding

  • Regeneron Pharmaceuticals, Inc.

Fingerprint

Central Nervous System Neoplasms
Radiotherapy
Pharmacokinetics
Pediatrics
Safety